Stock YMAB Y-MABS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
14.71 USD -0.88% Intraday chart for Y-mAbs Therapeutics, Inc. -2.78% +115.69%
03-14 Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign MT
03-14 Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18
Y-mabs Therapeutics Insider Bought Shares Worth $521,294, According to a Recent SEC Filing
Y-mabs Therapeutics Insider Sold Shares Worth $795,383, According to a Recent SEC Filing
Y-mAbs Therapeutics Q3 Net Loss Narrows, Revenue Rises
Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Y-mAbs Therapeutics, Inc. Announces Management Changes
Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
Y-mAbs Therapeutics Gets US FDA Clearance for Investigational New Drug Application for CD38-SADA
Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil
Insider Buy: Y-mabs Therapeutics
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. YMAB Stock
  4. News Y-mAbs Therapeutics, Inc.
  5. Other languages